ReviewThe Canadian journal of hospital pharmacy
Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.
Review in The Canadian journal of hospital pharmacy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2023Trial
- Trial
- Azithromycin and doxycycline intravenous and oral administrations before and after prescriber-facing alert for intravenous fluid conservation.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- PO-llution control: a cross-sectional study on the role of antimicrobial stewardship in reducing healthcare's carbon footprint.JAC-antimicrobial resistance · 2025Article
- Transitioning to oral therapy compared to IV inAnnals of medicine and surgery (2012) · 2025Article
- Use of Parenteral Antibiotics in Emergency Departments: Practice Patterns and Class Concordance.The western journal of emergency medicine · 2024Article
- Antibiotic prescribing to inpatients in Limpopo, South Africa: a multicentre point-prevalence survey.Antimicrobial resistance and infection control · 2023Article
- In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program.The Journal of antimicrobial chemotherapy · 2023Article
- Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-FiberAntimicrobial agents and chemotherapy · 2023Article
- Opportunities, associations, and impact of early intravenous to oral antimicrobial switch for hospitalized patients in Ethiopia.SAGE open medicine · 2023Article
- Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.Tuberculosis (Edinburgh, Scotland) · 2022Article
- Post-traumatic endophthalmitis prophylaxis: a systematic review and meta-analysis.Journal of ophthalmic inflammation and infection · 2022Article
- Article
- From basic to advanced computerised intravenous to oral switch for paracetamol and antibiotics: an interrupted time series analysis.BMJ open · 2022Review
- Oral or intravenous antibiotics?Australian prescriber · 2020Review
- Antimicrobial Stewardship at the Core of COVID-19 Response Efforts: Implications for Sustaining and Building Programs.Current infectious disease reports · 2020Review
- The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.Expert opinion on pharmacotherapy · 2019Review
- Intravenous-to-oral antibiotic switch therapy: a cross-sectional study in critical care units.BMC infectious diseases · 2019Article
- Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.JAMA internal medicine · 2019Article
- Inappropriateness of Intravenous Antibiotic Prescriptions at Hospital Discharge at a Tertiary Care hospital in Thailand.Drug, healthcare and patient safety · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany health care institutions are in the process of establishing antimicrobial stewardship programs. Changing the route of administration of antimicrobial agents from intravenous to oral (IV to PO) is a simple, well-recognized intervention that is often part of an antimicrobial stewardship program. However, the attending health care team may have concerns about making this switch.
objectivesTo provide insights into common concerns related to IV to PO conversion, with the aim of helping antimicrobial stewardship teams to address them. DATA SOURCES: Published clinical trials and reviews were identified from a literature search of Ovid MEDLINE with the keywords (step down or switch or conversion or transition or sequential) and (antibiotics or antibacterial agents or antimicrobial or anti-infective agents). DATA SYNTHESIS: The following issues are addressed in this review: benefits of the oral route, serum concentrations yielded by the oral formulation, source of pharmacokinetic data, clinical outcomes, provision of care in the intensive care unit, fear of therapeutic failure, and administration of antimicrobials via feeding tube.
conclusionsWhen considering a change to oral therapy, it is important to have a thorough understanding of key aspects of the antimicrobial agent, the patient, and the disease being treated. The antimicrobial stewardship team has an important role in facilitating IV to PO conversion, educating prescribers, and addressing any concerns or reservations that may interfere with timely transition from IV to PO administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.